Catalog No.
KDC09605
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
0.31-5 μg/mL
Sensitivity
0.156 μg/ml
Precision
CV<20%
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Alternative Names
MCLA-128, PB4188, R040517, CAS: 1969309-56-5
Background
Zenocutuzumab, an investigational bispecific antibody, has shown early efficacy in an ongoing phase I/II study of patients with tumors harboring NRG1 fusions. The data so far appear particularly promising in NRG1 fusion-positive pancreatic ductal adenocarcinoma, which tends to occur in younger patients.
Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration., PMID:40397846
eNRGy: Making progress toward a future for NRG1 fusion-positive cancer., PMID:40220746
Emerging importance of HER3 in tumorigenesis and cancer therapy., PMID:40087402
Zenocutuzumab: First Approval., PMID:39994106
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours., PMID:39979643
Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review., PMID:39971274
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer., PMID:39908431
NRG1 Fusions: The New Kid on the Block., PMID:39888568
The use of zenocutuzumab for NRG1 fusion-positive tumors., PMID:39820371
Zenocutuzumab (Bizengri) for NSCLC and pancreatic adenocarcinoma., PMID:39819990
Antibodies to watch in 2025., PMID:39711140
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions., PMID:38348690
Antibodies to watch in 2024., PMID:38178784
Profiling of gene fusion involving targetable genes in Chinese gastric cancer., PMID:36160735
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)., PMID:36107417
Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion-Positive, Estrogen Receptor-Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor., PMID:35977350
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements., PMID:35135829
Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines., PMID:35035535
[Not Available]., PMID:34969512
Zenocutuzumab Shines in PDAC., PMID:34112697
NRG1 fusions: Biology to therapy., PMID:34098222
The Exciting New Field of HER2-Low Breast Cancer Treatment., PMID:33804398
Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors., PMID:32006223
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade., PMID:29763625
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose., PMID:29728897
A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1., PMID:28655766
For research use only. Not for human or drug use.
